# DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Source: https://onco.cc/trials/nct07288112/  
OnCo record `nct07288112` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DOC1021 in melanoma, run by Diakonos Oncology Corporation, now recruiting.

## Summary

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma is a phase 1/2 interventional study registered as NCT07288112 by Diakonos Oncology Corporation, with 35 participants planned, started 2026-04-06 and due to reach its primary completion in 2031-01. Interventions recorded: DOC1021, Tumor resection and pIFN (peginterferon alfa-2a).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07288112
- Phase: 1/2
- Setting: Clinical Study of DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- Sponsor: Diakonos Oncology Corporation
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT07288112: https://clinicaltrials.gov/study/NCT07288112

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Diakonos Oncology](https://onco.cc/companies/diakonos-oncology/)
- drugs: [DOC1021](https://onco.cc/drugs/doc1021/)

---
JSON: https://onco.cc/api/v1/entities/nct07288112.json